

Laetitia Dou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4595058/publications.pdf>

Version: 2024-02-01

37
papers

3,567
citations

218677

26
h-index

377865

34
g-index

37
all docs

37
docs citations

37
times ranked

3969
citing authors

#	ARTICLE	IF	CITATIONS
1	The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. <i>Kidney International</i> , 2004, 65, 442-451.	5.2	421
2	The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1302-1308.	3.8	359
3	Endothelium structure and function in kidney health and disease. <i>Nature Reviews Nephrology</i> , 2019, 15, 87-108.	9.6	292
4	Elevation of circulating endothelial microparticles in patients with chronic renal failure. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 566-573.	3.8	287
5	The Cardiovascular Effect of the Uremic Solute Indole-3 Acetic Acid. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 876-887.	6.1	239
6	Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. <i>Kidney International</i> , 2013, 84, 733-744.	5.2	205
7	The Aryl Hydrocarbon Receptor-Activating Effect of Uremic Toxins from Tryptophan Metabolism: A New Concept to Understand Cardiovascular Complications of Chronic Kidney Disease. <i>Toxins</i> , 2014, 6, 934-949.	3.4	194
8	Vascular Incompetence in Dialysis Patientsâ€™ Proteinâ€™Bound Uremic Toxins and Endothelial Dysfunction. <i>Seminars in Dialysis</i> , 2011, 24, 327-337.	1.3	158
9	PROGRESS IN UREMIC TOXIN RESEARCH: Proteinâ€™Bound Toxinsâ€™ Update 2009. <i>Seminars in Dialysis</i> , 2009, 22, 334-339.	1.3	139
10	Transplanted Late Outgrowth Endothelial Progenitor Cells as Cell Therapy Product for Stroke. <i>Stem Cell Reviews and Reports</i> , 2011, 7, 208-220.	5.6	132
11	Does Uremia Cause Vascular Dysfunction. <i>Kidney and Blood Pressure Research</i> , 2011, 34, 284-290.	2.0	122
12	Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1576-1584.	3.8	94
13	P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. <i>Kidney International</i> , 2002, 62, 1999-2009.	5.2	88
14	P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. <i>Thrombosis and Haemostasis</i> , 2004, 92, 140-150.	3.4	85
15	Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease. <i>Kidney International</i> , 2018, 93, 986-999.	5.2	79
16	Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3381-3390.	0.7	74
17	Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1834-1841.	0.7	73
18	Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease. <i>Toxins</i> , 2018, 10, 412.	3.4	65

#	ARTICLE	IF	CITATIONS
19	Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 2281-2286.	2.3	63
20	Plasma Xanthine Oxidase Activity Is Predictive of Cardiovascular Disease in Patients with Chronic Kidney Disease, Independently of Uric Acid Levels. <i>Nephron</i> , 2015, 131, 167-174.	1.8	60
21	Adsorption of the uremic toxin p-cresol onto hemodialysis membranes and microporous adsorbent zeolite silicalite. <i>Journal of Biotechnology</i> , 2006, 123, 164-173.	3.8	51
22	Guanidino Compounds as Cause of Cardiovascular Damage in Chronic Kidney Disease: An in vitro Evaluation. <i>Blood Purification</i> , 2010, 30, 277-287.	1.8	49
23	Protein-bound uremic retention solutes. <i>Advances in Chronic Kidney Disease</i> , 2003, 10, 310-320.	2.1	44
24	Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor/nuclear factor-kappa B signaling pathway in human endothelial cells. <i>Archives of Toxicology</i> , 2019, 93, 121-136.	4.2	43
25	Endothelial Toxicity of High Glucose and its by-Products in Diabetic Kidney Disease. <i>Toxins</i> , 2019, 11, 578.	3.4	32
26	Circulating microparticles in renal diseases. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2129-2132.	0.7	26
27	Effect of uremia and hemodialysis on soluble L-selectin and leukocyte surface CD11b and L-selectin. <i>American Journal of Kidney Diseases</i> , 1998, 31, 67-73.	1.9	21
28	Quantitative Analysis of Leukocyte Membrane Antigen Expression on Human Fetal and Cord Blood: Normal Values and Changes during Development. <i>Clinical Immunology and Immunopathology</i> , 1997, 84, 56-64.	2.0	20
29	Aryl Hydrocarbon Receptor Activation and Tissue Factor Induction by Fluid Shear Stress and Indoxyl Sulfate in Endothelial Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2392.	4.1	17
30	The harmful effect of indoxyl sulfate on neovascularization in chronic kidney disease. <i>Kidney International</i> , 2016, 89, 532-534.	5.2	13
31	Mechanisms of myostatin and activin A accumulation in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1249-1260.	0.7	11
32	Neutrophil:lymphocyte ratio correlates with the uremic toxin indoxyl sulfate and predicts the risk of death in patients on hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2528-2537.	0.7	6
33	Reversing endothelial dysfunction with empagliflozin to improve cardiomyocyte function in cardiorenal syndrome. <i>Kidney International</i> , 2021, 99, 1062-1064.	5.2	4
34	CD146 at the Interface between Oxidative Stress and the Wnt Signaling Pathway in Systemic Sclerosis. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3200-3210.e5.	0.7	1
35	Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro—towards a standardized approach for research on uraemia. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1468-1468.	0.7	0
36	Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro—towards a standardized approach for research on uraemia. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 780-780.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Cell signalling / Pathophysiology. Nephrology Dialysis Transplantation, 2012, 27, ii77-ii85.	0.7	0